U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07524322) titled 'Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors' on March 31.
Brief Summary: This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer.
Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.
Study Start Date: April, 2026
Study Type: INTERVENTIONA...